A 32-assessment male tumor susceptibility panel interrogates thirty-two cancer-predisposition genes in a single blood draw. Where a smaller six-gene panel covers the highest-yield syndromes, this broader panel is designed for situations where clinical suspicion of a hereditary syndrome persists even when the initial smaller panel has returned negative or where the patient's history demands wider pathway coverage.
The clinical context in which this expanded panel adds particular value is the post-treatment setting. Once a patient has completed first-line therapy for a primary cancer, the question that drives subsequent management is no longer what to do first but what to do next. Surveillance, risk reduction, and cascade testing of family members become central, and each of these decisions benefits from a more complete genetic picture.
After first-line therapy, several decisions need to be revisited. Surveillance intensity, choice of secondary prevention strategies, and consideration of family testing all benefit from a refined risk estimate. A negative six-gene panel can leave the clinician with persistent suspicion, particularly when the patient's personal or family history does not fit neatly into the syndromes covered by the small panel. The 32-assessment panel extends the search to genes implicated in less common hereditary syndromes, in DNA repair pathways beyond mismatch repair and homologous recombination, and in genes linked to rare familial cancer clusters.
Per NCCN surveillance guidelines, the intensity and modality of follow-up after first-line therapy are modulated by germline risk. A patient whose expanded panel returns a likely pathogenic variant in a moderate-penetrance gene may move to a more intensive imaging schedule, may be referred for risk-reducing consultations, and may have first-degree relatives offered cascade testing. The expanded panel therefore functions as a precision-surveillance tool, not as a diagnostic test for recurrence.
A 32-gene panel is technically more challenging than a six-gene panel. The expanded gene list includes regions with higher rates of benign population variants and regions where the evidence base for pathogenicity is still maturing. Per ACMG standards, laboratories must classify each variant carefully, and the rate of variants of uncertain significance rises with panel size. Clinicians and patients should be prepared for VUS results and understand that they do not currently change management.
The clinical report from a 32-assessment panel should be returned through a genetics professional so that the patient understands the distinction between actionable pathogenic findings, non-actionable VUS findings, and negative results.
Q: When is a 32-assessment panel preferred over a six-gene panel? A: When clinical suspicion of a hereditary syndrome remains high after a negative six-gene result, or when the family history suggests a syndrome outside the most common pathways.
Q: Does the expanded panel predict treatment resistance? A: No. It predicts hereditary risk and informs surveillance, not response to a specific therapy.
Q: Will this expanded panel produce many variants of uncertain significance? A: A larger gene list typically yields more findings whose significance is not yet established. Per ACMG standards, these are not used for clinical decisions but may be reclassified later.
Q: Who should order this panel? A: Per NCCN, germline testing should be ordered through a clinician with genetics expertise who can interpret results, counsel the patient and arrange cascade testing of relatives.
A 32-assessment male tumor susceptibility panel interrogates thirty-two cancer-predisposition genes in a single blood draw. Where a smaller six-gene panel covers the highest-yield syndromes, this broader panel is designed for situations where clinical suspicion of a hereditary syndrome persists even when the initial smaller panel has returned negative or where the patient's history demands wider pathway coverage.
The clinical context in which this expanded panel adds particular value is the post-treatment setting. Once a patient has completed first-line therapy for a primary cancer, the question that drives subsequent management is no longer what to do first but what to do next. Surveillance, risk reduction, and cascade testing of family members become central, and each of these decisions benefits from a more complete genetic picture.
After first-line therapy, several decisions need to be revisited. Surveillance intensity, choice of secondary prevention strategies, and consideration of family testing all benefit from a refined risk estimate. A negative six-gene panel can leave the clinician with persistent suspicion, particularly when the patient's personal or family history does not fit neatly into the syndromes covered by the small panel. The 32-assessment panel extends the search to genes implicated in less common hereditary syndromes, in DNA repair pathways beyond mismatch repair and homologous recombination, and in genes linked to rare familial cancer clusters.
Per NCCN surveillance guidelines, the intensity and modality of follow-up after first-line therapy are modulated by germline risk. A patient whose expanded panel returns a likely pathogenic variant in a moderate-penetrance gene may move to a more intensive imaging schedule, may be referred for risk-reducing consultations, and may have first-degree relatives offered cascade testing. The expanded panel therefore functions as a precision-surveillance tool, not as a diagnostic test for recurrence.
A 32-gene panel is technically more challenging than a six-gene panel. The expanded gene list includes regions with higher rates of benign population variants and regions where the evidence base for pathogenicity is still maturing. Per ACMG standards, laboratories must classify each variant carefully, and the rate of variants of uncertain significance rises with panel size. Clinicians and patients should be prepared for VUS results and understand that they do not currently change management.
The clinical report from a 32-assessment panel should be returned through a genetics professional so that the patient understands the distinction between actionable pathogenic findings, non-actionable VUS findings, and negative results.
Q: When is a 32-assessment panel preferred over a six-gene panel? A: When clinical suspicion of a hereditary syndrome remains high after a negative six-gene result, or when the family history suggests a syndrome outside the most common pathways.
Q: Does the expanded panel predict treatment resistance? A: No. It predicts hereditary risk and informs surveillance, not response to a specific therapy.
Q: Will this expanded panel produce many variants of uncertain significance? A: A larger gene list typically yields more findings whose significance is not yet established. Per ACMG standards, these are not used for clinical decisions but may be reclassified later.
Q: Who should order this panel? A: Per NCCN, germline testing should be ordered through a clinician with genetics expertise who can interpret results, counsel the patient and arrange cascade testing of relatives.
english
français
Deutsch
Italiano
Русский
Español
português
Nederlandse
ελληνικά
日本語
한국
العربية
हिन्दी
Türkçe
indonesia
tiếng Việt
ไทย
বাংলা
فارسی
polski
